ZCA
ACHN

Zeke Capital Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Zeke Capital Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,530
Closed -$30K – 777
2018
Q2 		$30K Buy
+10,530
New +$35.9K ﹤0.01% 630

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Zeke Capital Advisors's ACHN Position: Q3 2018 in Review

Zeke Capital Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2018, closing a stake of 10,530 shares — an estimated $30K sold.

Zeke Capital Advisors first reported a position in ACHN in Q2 2018 and held it in 1 quarter. The position peaked at $30K in Q2 2018. 137 funds tracked by Wall St. Rank hold ACHN as of Q3 2018.

  • Zeke Capital Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Zeke Capital Advisors sold 10,530 Achillion Pharmaceuticals shares in Q3 2018, an estimated $30K.
  • Zeke Capital Advisors first reported a position in Achillion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Zeke Capital Advisors's Achillion Pharmaceuticals position peaked at $30K in Q2 2018.
  • 137 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2018.

Based on Zeke Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.